Mer511 (sc)

Phase 1

MMerida Biosciences

Mer511 (sc) is one of 11 therapeutic programs targeting Graves disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Graves DiseaseRecruiting

Graves DiseasePhase 1

Recruiting

Competition

Competitive Landscape

20 competitors in Graves Disease

#DrugCompanyPhaseTrials

Tapazole

VViking Therapeutics, Inc.

Approved

6 2

Synthroid

IInstitut Jerome Lejeune

Approved

—3

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—5

Decadron

AAspen Global Incorporated

Approved

—6

Potassium Iodide

DDawnrays Pharmaceutical (Holdings) Limited

Phase 3

1 7

IMVT-1402

IImmunovant Sciences GmbH

Phase 2

3 8

Efgartigimod PH20 SC

Argenx

Phase 3

2 9

BHV-1300

BBiohaven Therapeutics Ltd.

Phase 3

2 10

Rilzabrutinib Dose 2

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Graves Disease

NCT07305818

Clinical

Trials by Indication[1]

Graves disease1 trial

A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease

Recruiting·MMerida Biosciences·Phase 1·NCT07305818·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mer511 (sc). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mer511 (sc). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merida Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: MMerida Biosciences

Mer511 (sc)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Graves disease1 trial

References

Drug Info

Quick Facts

Related News